PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Empagliflozin - Heart failure

PAD Profile : Empagliflozin - Heart failure

Keywords :
SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, chronic heart failure, CHF, HFrEF, reduced ejection fraction
Brand Names Include :
Jardiance

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin:

  • as an option for treating adult chronic heart failure with reduced ejection fraction in addition to standard care (NICE TA773)
  • as an option for treating adult chronic heart failure with preserved or mildly reduced ejection fraction in addition to standard care (NICE TA929)

Treatment should be initiated or recommended by a heart failure specialist in patients with a formal diagnosis of heart failure as per NICE guideline on Chronic Heart Failure in adults

Heart Failure specialist defined as:

 • Cardiology consultant, specialist, or registrar

 • Heart failure specialist nurse

 • GP with a specialist interest in heart failure or GP cardiologist

 • General physician with heart failure expertise

 • Renal physician

02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a BLUE information sheet for empagliflozin and dapagliflozin for Adult Heart Failure with reduced ejection fraction (HFrEF) and a place in therapy document for these treatments in patients with Heart Failure.

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More